Granules India Limited recently informed exchanges that the company completed a US Food and Drug Administration (USFDA) inspection at its Gagillapur facility in Hyderabad, Telangana. The inspection, which lasted from August 26 to September 6, 2024, concluded with six observations.
In the exchange filing, the company shared, “The recent inspection covered both Current Good Manufacturing Practice (cGMP) and Pre-Approval Inspection (PAI) processes. Granules India is committed to addressing the observations promptly and will submit its response to the USFDA within the stipulated timeframe. The Gagillapur facility continues to play a vital role in the company’s global operations, ensuring the supply of high-quality pharmaceutical products to markets worldwide.”
Granules India Limited, established in 1991, is a vertically integrated fast-growing Indian pharmaceutical firm headquartered in Hyderabad. It has the best facilities and is committed to operational excellence, quality and customer service.
